Methods for Use of a Specific Anti-Angiogenic Adenoviral Agent
OwnerYael COHEN, Naamit Sher +3inventors
InventorsYael COHEN, Naamit Sher, Erez Feige, Livnat Bangio, Eyal Breitbart
Life of this patent
Estimating the term…
Abstract
Anti-angiogenic adenovirus vectors, and therapeutic use thereof are provided, and more particularly, but not exclusively, clinical protocols for treatment of solid tumors in patients with an Ad5-PPE-1-3X-fas-chimera adenovirus vector.
Claims46
A method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a non-replicating adenovirus vector, wherein said vector comprises a polynucleotide which comprises a fas-chimera transgene transcriptionally linked to a murine pre-proendothelin promoter, wherein said therapeutically effective amount is at least 1×108 virus particles.
(canceled)
(canceled)
(canceled)
(canceled)
-37. (canceled)
-65. (canceled)
(canceled)
(canceled)
A kit for treating a solid tumor in a subject in need thereof, comprising a unit dosage of virus particles of a non-replicating adenovirus vector comprising the polynucleotide sequence as set forth in SEQ ID NO:
- 9 or 10 wherein said non-replicating adenovirus vector is formulated for intravenous administration, and instructions for administration of said adenovirus.
(canceled)
(canceled)
A method for administering a therapeutic composition comprising an adenoviral vector to a subject, comprising administering a therapeutically effective amount of the composition to the subject at least twice, wherein the administering does not induce a dose-dependent increase in anti-adenovirus antibodies against said adenoviral vector in the subject.
-82. (canceled)
(canceled)
(canceled)
An adenovirus vector comprising the polynucleotide sequence as set forth in SEQ ID NO:
- 9.
An adenovirus vector comprising the polynucleotide sequence as set forth in SEQ ID NO:
- 10.
Dependencies are inferred from the claim text.